Immunotherapy before surgery shows promise for aggressive uterine cancer
NCT ID NCT06180733
First seen May 13, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study tests whether giving the immunotherapy drug pembrolizumab before standard hysterectomy can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their surgery. The main goal is to see how many have a major response in the tumor tissue, which will help design a larger future study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Medical Centre Groningen
Groningen, Provincie Groningen, 9700 RB, Netherlands
Conditions
Explore the condition pages connected to this study.